Bloodstream Infections Caused by Multidrug Resistant Bacteria: Clinical and Microbiological Features and Mortality
暂无分享,去创建一个
[1] J. Rodríguez-Baño,et al. Treatments and Predictors of Mortality for Carbapenem-Resistant Gram-Negative Bacilli Infections in Malaysia: A Retrospective Cohort Study , 2022, Tropical medicine and infectious disease.
[2] F. D. De Rosa,et al. Ten Years of KPC-Kp Bloodstream Infections Experience: Impact of Early Appropriate Empirical Therapy on Mortality , 2022, Biomedicines.
[3] Y. Hassan,et al. Association of Multidrug Resistance Bacteria and Clinical Outcomes of Adult Patients with Sepsis in the Intensive Care Unit , 2022, Tropical medicine and infectious disease.
[4] G. d’Ettorre,et al. Time to Effective Therapy Is an Important Determinant of Survival in Bloodstream Infections Caused by Vancomycin-Resistant Enterococcus spp , 2022, International journal of molecular sciences.
[5] Yongqiang Yang,et al. Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China , 2022, Infection and drug resistance.
[6] E. Petinaki,et al. Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012–2016) , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[7] K. Laupland,et al. Population-based risk factors for community-onset bloodstream infections , 2019, European Journal of Clinical Microbiology & Infectious Diseases.
[8] C. Vandenbroucke-Grauls,et al. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review , 2019, Antimicrobial Resistance & Infection Control.
[9] M. Reis,et al. Bloodstream infections caused by multidrug-resistant gram-negative bacteria: epidemiological, clinical and microbiological features , 2019, BMC Infectious Diseases.
[10] K. Laupland,et al. Risk factors associated with bloodstream infections in end-stage renal disease patients: a population-based study , 2018, Infectious diseases.
[11] E. Giné,et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance , 2018, PloS one.
[12] K. Garey,et al. Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms , 2017, Journal of clinical gastroenterology.
[13] Wen-Hung Wang,et al. The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[14] J. Thaden,et al. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria , 2017, Antimicrobial Agents and Chemotherapy.
[15] S. Harthug,et al. Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study , 2017, BMC Infectious Diseases.
[16] R. Kullar,et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. , 2017, The Lancet. Infectious diseases.
[17] S. Yavuz,et al. Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. , 2016, The Journal of hospital infection.
[18] D. Szabo,et al. Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children , 2016, Infection.
[19] K. Peck,et al. Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections , 2016, The Korean journal of internal medicine.
[20] P. Savelkoul,et al. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam , 2016, The Journal of antimicrobial chemotherapy.
[21] N. Taneja,et al. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria , 2016, Microbiology insights.
[22] Adil Rafiq Rather,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .
[23] Alan P. Johnson,et al. Antibiotic Stewardship Initiatives as Part of the UK 5-Year Antimicrobial Resistance Strategy , 2015, Antibiotics.
[24] G. B. Orsi,et al. Changed epidemiology of ICU acquired bloodstream infections over 12 years in an Italian teaching hospital. , 2015, Minerva anestesiologica.
[25] N. Safdar,et al. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis , 2015, Infection.
[26] G. Rossolini,et al. Update on the antibiotic resistance crisis. , 2014, Current opinion in pharmacology.
[27] D. Church,et al. Population-Based Epidemiology and Microbiology of Community-Onset Bloodstream Infections , 2014, Clinical Microbiology Reviews.
[28] C. Giaquinto,et al. Current management of late onset neonatal bacterial sepsis in five European countries , 2014, European Journal of Pediatrics.
[29] A. Marra,et al. Nosocomial Bloodstream Infections in Brazilian Pediatric Patients: Microbiology, Epidemiology, and Clinical Features , 2013, PloS one.
[30] M. Al-Hasan,et al. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[31] M. Antonelli,et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study , 2012, Intensive Care Medicine.
[32] K. Kaye,et al. Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli , 2012, Antimicrobial Agents and Chemotherapy.
[33] A. Marra,et al. Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of 2,563 Cases from a Prospective Nationwide Surveillance Study , 2011, Journal of Clinical Microbiology.
[34] Miguel Calvo Rebollar,et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. , 2011, The Journal of antimicrobial chemotherapy.
[35] Vincent H Tam,et al. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. , 2010, The Journal of antimicrobial chemotherapy.
[36] L. Dijkshoorn,et al. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.
[37] Daniel J Sexton,et al. Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.
[38] H. Sørensen,et al. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] S. Chevret,et al. A one-year prospective study of nosocomial bacteraemia in ICU and non-ICU patients and its impact on patient outcome. , 2000, Journal of Hospital Infection.
[40] D. Pittet,et al. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. , 1995, Archives of internal medicine.
[41] Jay Steingrub,et al. International study of the prevalence and outcomes of infection in intensive care units , 2009 .
[42] R. Ramphal,et al. Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.